ArticleFrontiers in endocrinology2026
A clinical nomogram for evaluating occult central lymph node metastasis in clinically low-risk, unifocal papillary thyroid microcarcinoma.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop and validate a clinical nomogram to predict the risk of central lymph node metastasis (CLNM) in patients with clinically low-risk papillary thyroid microcarcinoma (PTMC). Methods: Patients with clinically low-risk PTMC were enrolled in this retrospective cohort study. Potential predictive factors include sex, age, tumor size, tumor location, and Hashimoto's thyroiditis (HT). Independent predictive factors were identified using multivariate logistic regression and a nomogram was developed using the finalized model. The performance of the model was evaluated using receiver operating characteristic (ROC) curve analysis, calibration plots, and decision curve analysis (DCA). Results: This study included 4,201 patients with clinically low-risk unifocal PTMC, of whom 1,553 (37.0%) presented with CLNM. Multivariate logistic regression analysis revealed four independent predictive factors: sex, age, tumor size, and tumor location. The constructed nomogram demonstrated moderate predictive performance, with an area under the ROC curve (AUC) of 0.700 (95% confidence interval [CI]: 0.680-0.719) in the training cohort and 0.697 (95% CI: 0.667-0.727) in the validation cohort. Furthermore, the fit of the calibration curves was good, and the DCA results suggest potential clinical utility for patient benefit. Conclusion: A clinical nomogram incorporating sex, age, tumor size, and tumor location was developed and internally validated. This tool achieved moderate predictive accuracy for estimating the risk of CLNM in patients with clinically low-risk unifocal PTMC. This screening-level model may provide auxiliary clinical value for outpatient consultation. It can aid clinicians in patient counselling and facilitate preliminary risk stratification and clinician-patient communication for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.